Related Experiment Videos
Strategies for combination therapy in hypertension
1Temple University School of Medicine (Clinical Campus), Pittsburgh, Pennsylvania 15232, USA. gradmana@temple.edu
Insights
Effective hypertension management often requires multiple medications. This review highlights rational drug combinations and efficient strategies for better blood pressure control and reduced cardiovascular events in patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Hypertension Management
Background:
- Most patients require multiple antihypertensive agents to reach target blood pressure (BP) goals.
- Hypertension affects over 46 million ambulatory care visits annually in the U.S.
- Current guidelines necessitate combination therapy for effective BP management.
Purpose of the Study:
- To review rational selection of effective antihypertensive drug combinations.
- To discuss efficient strategies for using combination therapy to achieve therapeutic objectives.
- To address the evolving landscape of hypertension treatment.
Main Methods:
- Literature review focusing on evidence-based antihypertensive combination therapies.
- Analysis of pharmacological principles for additive BP reduction.
- Evaluation of clinical trial data on drug combinations and patient outcomes.
Main Results:
- Recommended combinations offer complementary pharmacology and additive BP reduction.
- Chlorthalidone is increasingly favored over hydrochlorothiazide.
- Mineralocorticoid antagonists are key for resistant hypertension.
- Strategies evolve towards low-dose combinations and earlier initiation.
Conclusions:
- Judicious use of drug combinations is crucial for achieving BP targets and reducing cardiovascular endpoints.
- Evolving strategies include low-dose combinations and early initiation, especially for Stage 2 hypertension.
- Optimizing combination therapy improves patient outcomes in hypertension management.
Purpose Of Review:
To achieve the target blood pressure (BP) mandated by current guidelines, a large majority of patients require simultaneous administration of multiple antihypertensive agents. The purpose of this review is to focus attention on the rational selection of effective drug combinations, and upon ways to use them efficiently to achieve therapeutic objectives. The topic is widely relevant given that more than 46 million ambulatory care visits are conducted in the United States annually for hypertension management.
Recent Findings:
Recommended drug combinations exhibit complimentary pharmacology and additive BP reduction, are well tolerated, and include components with demonstrated endpoint reduction in long-term clinical trials. Recently, the choice of diuretics has emerged as a controversial issue with some evidence favoring the long-acting agent, chlorthalidone, in preference to hydrochlorothiazide. For resistant hypertension, mineralocorticoid antagonists are increasingly used as preferred add-on agents. Practical strategies for the optimal use of combination therapy continue to evolve from the older stepped-care approach to the use of low-dose combinations, and to initiation of combination therapy in a broader range of hypertensive patients.
Summary:
Thoughtful use of drug combinations is critical for achieving therapeutic objectives in hypertensive individuals and populations - more rapid BP control and more effective endpoint reduction. Practical strategies for the optimal use of combination therapy continue to evolve from the older stepped-care approach to more recent recommendations favoring the use of low-dose combinations, and initiation therapy of combination treatment, particularly in patients with Stage 2 hypertension.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Hypertension V: Nursing Management
Atherosclerosis III: Management
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...